🇺🇸 FDA
Pipeline program

AGN 211745

211745-001

Phase 2 small_molecule terminated

Quick answer

AGN 211745 for Choroid Neovascularization is a Phase 2 program (small_molecule) at Allergan Pharmaceuticals International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Allergan Pharmaceuticals International Limited
Indication
Choroid Neovascularization
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials